Resverlogix (TSX:RVX) Change In Other Working Capital : C$-0.07 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Change In Other Working Capital?

Resverlogix's Change In Other Working Capital for the quarter that ended in Mar. 2024 was C$-0.06 Mil. It means Resverlogix's Other Working Capital declined by C$0.06 Mil from Dec. 2023 to Mar. 2024 .

Resverlogix's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was C$0.00 Mil. It means Resverlogix's Other Working Capital increased by C$0.00 Mil from Dec. 2022 to Dec. 2023 .

Resverlogix Change In Other Working Capital Historical Data

The historical data trend for Resverlogix's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Change In Other Working Capital Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Change In Other Working Capital

Get a 7-Day Free Trial

-8.41

-0.21

0.36

0.01

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial															-0.03	2.18	-2.19	-	-0.06

Resverlogix Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.07 Mil.

Resverlogix Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Resverlogix's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines